Back
Corporate News
Under scheme of amalgamation
Suven Pharmaceuticals allots 12.80 cr equity shares
09-May-2025, 09:58
Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value of Re 1 each to the eligible shareholders of Cohance Lifesciences (transferor company) in share exchange ratio of 11:295 in terms of the scheme of amalgamation.
Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value of Re 1 each to the eligible shareholders of Cohance Lifesciences (transferor company) in share exchange ratio of 11:295 in terms of the scheme of amalgamation.
Powered by Capital Market - Live News